Werewolf Therapeutics (HOWL) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Oncolytics Biotech (ONCY) over the past year, gaining 8.4% versus a loss of 65.0%. Over five years, ONCY leads with a -80.7% price change compared with -93.7% for HOWL. Oncolytics Biotech is the larger company by market cap ($47.7 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | ONCY |
|---|---|---|
| Share price | $0.9466 | $0.3501 |
| Market cap | $46.00M | $47.66M |
| 1-day change | -3.97% | -10.37% |
| YTD return | +49.31% | -59.76% |
| 1-year return | +8.43% | -64.99% |
| 5-year return | -93.68% | -80.66% |
| EPS (TTM) | $-0.58 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-60.82M | $-28.76M |
| 52-week high | $1.20 | $1.30 |
| 52-week low | $0.27 | $0.33 |
| Distance from 52-week high | -21.12% | -73.07% |
| Analyst consensus | none | buy |
| Avg. price target upside | +639.49% | +1085.38% |
| Average volume | 1.08M | 1.17M |
| Shares outstanding | 48.60M | 136.14M |
| Employees | 39 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed ONCY by 73.4 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
HOWL vs ONCY FAQ
Which is bigger, Werewolf Therapeutics or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $47.66M compared with $46.00M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, HOWL or ONCY?
HOWL returned +8.43% over the past 12 months, compared with -64.99% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.